PHASE II International
PHASE II International is a privately held, London-based life science consultancy founded in 1997 that delivers pre-launch, launch, and lifecycle strategy, intelligence, and communications services to biopharmaceutical companies through a curated Network of Excellence model and an AI-powered practice area.
- Company typePrivate
- Founded1997
- HeadquartersThames Ditton, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
What PHASE II International does
PHASE II International is a privately held life science consultancy, founded in 1997 and incorporated in England and Wales, that delivers pre-launch, launch, and lifecycle strategy, intelligence, and communications services to biopharmaceutical companies. The firm operates through a curated 'Network of Excellence' model — a global roster of independent specialists in medical strategy, health economics, epidemiology, scientific writing, design, and AI — assembled bespoke for each client engagement under the personal oversight of its Executive Directors. Two engagement models structure delivery: Agency of Record (multi-year integrated strategic support) and Ad Hoc Consultancy (project-specific expertise, frequently for early-stage pipeline products).
The company sells three integrated service pillars: Market Intelligence Services (MLA, CBA, CPA, MM&F, CIS, KOL mapping); Strategy Development (eleven proprietary moderated workshop processes including Pre-Strat, TPPO, TCPO, SciPlat, PosStrat, ComStrat, ComPlan, SciPlan, MarPlan, BrandPlan, PatPlan); and Communication Programs (branded/unbranded creative campaigns, scientific congress booth development, video). A branded 'PHASE II | AI' practice overlays the core offering with NLP, machine learning predictive analytics (via partnership with PredictaMed for sub-clinical disease detection), and generative AI creative ideation. The customer base spans hematology, oncology, immunology, and rare disease, with named clients including BeOne, Almirall, Curis Pharma, and Pharvaris. A separate sister organization, Scientific Education Support (SES), delivers independent accredited medical education and is fully firewalled from the consultancy.
PHASE II International firmographics
Firmographics- Name
- PHASE II International
- Legal name
- PHASE II International Limited
- Website
- https://phase-ii.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- PHASE II International is a privately held, London-based life science consultancy founded in 1997 that delivers pre-launch, launch, and lifecycle strategy, intelligence, and communications services to biopharmaceutical companies through a curated Network of Excellence model and an AI-powered practice area.
- Ownership category
- akta.pro rank
PHASE II International industry classification
Industry- Product category
- Life Science Consultancy
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Post-Approval Clinical Development (Phase IV & Lifecycle Management) (HLAIALAJ)
- akta.pro secondary industry
- Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
Keywords
Where PHASE II International is headquartered
LocationHeadquarters
- HQ city
- Thames Ditton
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
PHASE II International business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales
Revenue model
- Market Intelligence Services: MLA (Market Landscape Analysis), CBA (Competitor Benchmarking Analysis), CPA (Customer Profiling Analysis), MM&F (Market Modelling & Forecasting), CIS (Competitor Intelligence Services), BIR (Bespoke Insight Research), KOL Identification & Influence Mapping
- Strategy Development Services: Pre-Strat, TPPO, TCPO, SciPlat, PosStrat, ComStrat, ComPlan, SciPlan, MarPlan, Thought leader advocacy planning, BrandPlan, PatPlan processes delivered through moderated workshops
- Communication Programs: Integrated Communications & Commercialization Planning, Project Implementation, Creative Advertising Campaigns (branded and unbranded), Scientific exhibition booth panels, Video production
- Agency of Record Engagements: Full array of integrated strategic services encompassing market research, analysis and intelligence services; strategic product and launch planning; and development/implementation of scientific, market access and creative medical communication programs
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom Professional Services |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
PHASE II International product offering
Product offeringCore offering
PHASE II International is a life science consultancy that helps biopharmaceutical companies plan, launch and lifecycle-manage products by delivering market intelligence, strategic planning and medical communications through a curated Network of Excellence of independent specialists. It bundles these capabilities into ongoing Agency of Record engagements and project-based Ad Hoc Consultancy assignments, with an embedded "PHASE II | AI" practice applying NLP, machine learning predictive analytics for early disease detection, and generative AI tools to its intelligence, strategy and creative workstreams.
Product overview
PHASE II International is a life science consultancy operating since 1997 through a curated 'Network of Excellence' — a virtual organization of independent specialists assembled bespoke for each client engagement. The company offers three integrated core service pillars: Market Intelligence Services (MLA, CBA, CPA, MM&F, CIS, BIR, KOL Identification), Strategy Development (Pre-Strat, TPPO, TCPO, SciPlat, PosStrat, ComStrat, ComPlan, SciPlan, MarPlan, BrandPlan, PatPlan), and Communication Programs (integrated communications and branded/unbranded creative advertising campaigns). These services are delivered across two engagement models — Agency of Record (ongoing strategic support) and Ad Hoc Consultancy (project-specific expertise) — primarily supporting biopharmaceutical companies in pre-launch, launch, and lifecycle phases across hematology, oncology, immunology, and rare disease. A distinct AI-powered practice area branded 'PHASE II | AI' overlays the core services with NLP for market research, machine learning predictive analytics for early disease detection and clinical trial patient matching, and generative AI tools for creative ideation. The company also maintains sister organization Scientific Education Support (SES) for independent accredited medical education, which is operationally firewalled from PHASE II.
Differentiator
Problem solved
Functional benefit
Products and services
- Market Intelligence Services A suite of market research and intelligence offerings for life science companies encompassing Market Landscape Analysis (MLA), Competitor Benchmarking Analysis (CBA), Customer Profiling Analysis (CPA), Market Modelling & Forecasting (MM&F), Competitor Intelligence Services (CIS), Bespoke Insight Research (BIR), and KOL Identification & Influence Mapping. Designed for Business Intelligence, Medical Affairs and Commercial teams seeking market intelligence, competitor benchmarking and strategic insights to support pre-launch and launch decisions.
- Strategy Development A portfolio of proprietary strategic planning processes delivered through moderated workshops: Pre-Strat (Pre-Clinical Candidate Selection), TPPO (Target Product Profile Optimization), TCPO (Target Clinical Profile Optimization), SciPlat (Scientific Platform & Core Claims), PosStrat (Product Positioning & Key Messages), ComStrat (Communications Strategy), ComPlan (Communication Planning), SciPlan (Scientific Publication Planning), MarPlan (Market Access Planning), Thought Leader Advocacy Planning, BrandPlan (Brand Communications Planning), and PatPlan (Patient Engagement & Advocacy Planning). For Medical Affairs, Clinical Development, Market Access and Commercial teams planning new product launches and lifecycle phases.
- Communication Programs Integrated communications and creative advertising campaigns (branded and unbranded) that translate complex scientific and technical information into clear, actionable messaging for healthcare professionals, patients, payers and the general public. Includes scientific exhibition booth panel development, video production and full project implementation. For Commercial and Marketing teams within biopharmaceutical companies.
- PHASE II | AI AI-powered practice area encompassing Natural Language Processing (NLP) for market research transcription, sentiment analysis (emotion detection) and report generation; machine learning algorithms and AI-powered analytics platforms for predictive analytics, early disease detection (up to five years pre-onset) and matching patients to open/recruiting clinical trials based on eligibility criteria; and generative creative design tools (DALL-E, GPT-3) for medical education and marketing communication ideation.
- Market Access & HEOR Services Market access strategies, optimized health economics outcomes research programs, and value demonstration communications for biopharmaceutical clients. Encompasses Systematic Literature Reviews (SLRs), Global Value Dossiers (GVDs), HTA submissions and implementation per EU country, and pathways to successful negotiation with local payers across EU countries. For Market Access teams seeking to demonstrate clinical and economic value of products.
- Strategic Advisory Board Services PHASE II-moderated Expert Advisory Boards covering global regions (US, Europe, Asia Pacific) supporting Phase 2-to-Phase 3 transition planning. Includes facilitation of consensus disease definitions, unmet clinical needs, target patient segmentation, TPP criteria, AI prediction models for disease identification, and inclusion/exclusion criteria for Phase 3 trials.
- Scientific Exhibition Booth Panel Development Full-service scientific exhibition booth panel development for international congresses (EHA, ASCO, ASH), encompassing research, copywriting, editing, referencing, original graphics creation using BioRender, high-resolution artwork preparation, and logistics management for delivery to congress venues. For biopharmaceutical companies seeking scientific presence at major international hematology and oncology congresses.
- Corporate Brand Communications Guide Comprehensive corporate brand identity development and documentation services for pharmaceutical and biotechnology companies, including logo usage guidelines, vision line application, typography standards, color palettes, imagery guidelines, advertising templates, presentation templates, scientific poster templates, corporate brochure templates, and style guidelines for devices and icons.
- Clinical Trial Center Mapping & Profiling Market intelligence service mapping and profiling clinical trial centers of excellence, including hospital type classification, hematology specialty, principal investigator details, patient volumes, Phase 1 facilities, and clinical trial participation status for both sponsor and competitor trials. For Clinical Development and Clinical Operations teams at biopharmaceutical sponsors.
Quantifiable outcome
- Supported over 30 life science companies and 35 life science brands since 1997
- +2 more outcomes
Companies that use PHASE II International
Customer profileNamed customers8 records
Segments5 records
Ideal customer profiles2 records
PHASE II International technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature5 records
PHASE II International partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- Network of Excellence (Associates & Partners)coreSince 1997, PHASE II has developed an extensive global Network of Excellence consisting of scientific and clinical thought leaders, discipline experts and associates as well as life science and academic partners. Key named partners include: Stephen Nicholson PhD (Medical Oncologist), Tim Hardman PhD (Senior Medical Strategist), Paul Miller PhD (Independent Health Economist), Melanie Martin MRPharmS (Director, A-Z Medical Writing), Susanne Gulliver BA MPH (Senior Epidemiologist), Felix Chapovsky MD (Medical Strategy Consultant), David Zsaritsky (President of The Agency Network, MJH Lifesciences), and many others across medical, creative, digital, health economics, market research, video production, and AI disciplines.
- The Agency Network (TAN), part of MJH LifesciencescoreDavid Zsaritsky serves as President of The Agency Network (TAN), part of MJH Lifesciences, acting as US Partner Agency to PHASE II International. This partnership extends PHASE II's reach into the US market.
- Patient Advocacy Groups & AssociationsminorPatient networks and associations PHASE II has collaborated with include: ALAN, Cancer Care, FOCiS, and Lymphoma Coalition. These partnerships support patient engagement and advocacy planning services.
- Medical SocietiesminorMedical societies PHASE II has collaborated with include ELI, ELN, ESH, and FoCiS. These partnerships support scientific engagement and thought leader activities.
- Scientific Education Support (SES)minorSES is PHASE II's sister organization specializing in independent and accredited medical education programs. Operations are completely firewalled from PHASE II. SES and PHASE II are separate legal entities.
- Niche Science & Technology LtdminorTim Hardman PhD, Managing Director of Niche Science & Technology Ltd, serves as Senior Scientific Strategist and Medical Writer. Represents strategic partnership for scientific writing capabilities.
- NewLab Clinical ResearchminorSusanne Gulliver BA MPH, Senior Epidemiologist, Research & Operations and CEO of NewLab Clinical Research. Represents strategic partnership for epidemiological research capabilities.
- Miller Economics LtdminorPaul Miller BA, MSc, PhD, Director at Miller Economics Ltd, serves as Value Demonstration/Health Economics Lead. Represents strategic partnership for health economics capabilities.
- Lessis MooreminorMaria Szmit, Director at Lessis Moore, provides Senior Graphic Design & UX capabilities. Represents strategic partnership for design services.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
PHASE II International competitors and assessment
Company assessmentDirect peers
- The Lockwood Group: Healthcare communications and consulting agency serving pharma and biotech with strategic planning and creative services. Comparable on launch strategy, KOL engagement and content development for life science clients.
- Trinity Life Sciences: Strategic consulting firm providing commercial strategy, market intelligence, and launch planning to biopharma clients. Directly comparable to PHASE II on the Strategy Development and Market Intelligence pillars of the offering.
- Healthcare Consultancy Group (HCG): Strategic consultancy supporting pharma and biotech with medical affairs, market access and patient engagement consulting. Comparable to PHASE II's strategic advisory and HEOR-related service lines.
- ApotheCom (Ashfield Health): Medical communications agency offering scientific engagement, publications planning and strategic services to biopharma. Directly comparable across PHASE II's medical affairs, publications and stakeholder engagement services.
- Fishawack Health (Inizio): Specialist medical communications and consulting group with global delivery across commercial, medical and patient engagement functions. Competes head-to-head on lifecycle and launch services for life science brands.
- Caudex (IPG Health): Medical communications and consulting agency serving pharma and biotech across launch and lifecycle. Closely aligned to PHASE II's medical affairs, market access and brand communications workstreams.
- Chameleon Communications (Inizio): Boutique medical communications agency focused on scientific storytelling and engagement for pharma clients. Overlaps with PHASE II's branded and unbranded creative, congress and advisory board support.
Broad incumbents
- Real Chemistry: Healthcare-focused marketing, communications and data analytics firm offering integrated commercial services to life science clients. Wider portfolio with data and technology capabilities beyond PHASE II's specialist footprint.
- IQVIA: Global life science services company providing commercial and clinical solutions including market intelligence, launch support and consulting. Competes on the data depth and global delivery scale that PHASE II lacks.
Emerging players
- Dudnyk (Inizio): Health communications agency with strong focus on rare disease and specialty therapeutics. Directly overlaps with PHASE II's rare disease launch work such as the Pharvaris HAE franchise.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
PHASE II International social profiles
Digital presencePHASE II International financial estimates
Financial estimateRevenue estimate
Valuation estimate
PHASE II International leadership team
Management profileNumber of profiles
Profiles2 records
PHASE II International funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PHASE II International M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PHASE II International
What does PHASE II International do?
PHASE II International is a life science consultancy that helps biopharmaceutical companies plan, launch and lifecycle-manage products by delivering market intelligence, strategic planning and medical communications through a curated Network of Excellence of independent specialists. It bundles these capabilities into ongoing Agency of Record engagements and project-based Ad Hoc Consultancy assignments, with an embedded "PHASE II | AI" practice applying NLP, machine learning predictive analytics for early disease detection, and generative AI tools to its intelligence, strategy and creative workstreams.
Is PHASE II International a public or private company?
PHASE II International is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was PHASE II International founded?
PHASE II International was founded in 1997. It employs 11 to 50 people.
Where is PHASE II International based?
PHASE II International is headquartered in Thames Ditton, United Kingdom, in the Europe region.
How does PHASE II International make money?
Four revenue lines are on record. Market Intelligence Services are the primary driver. The others are strategy Development Services, communication Programs and agency of Record Engagements.
Who are PHASE II International's main competitors?
Direct peers on record are The Lockwood Group, Trinity Life Sciences, Healthcare Consultancy Group (HCG), ApotheCom (Ashfield Health), Fishawack Health (Inizio), Caudex (IPG Health) and Chameleon Communications (Inizio). Broad incumbents are Real Chemistry and IQVIA. Dudnyk (Inizio) is listed as an emerging player.
Does PHASE II International have an API?
No public API is recorded for PHASE II International.
What industry is PHASE II International in?
PHASE II International's product category is Life Science Consultancy. Its primary akta.pro industry code is HLAIALAJ, Post-Approval Clinical Development (Phase IV & Lifecycle Management), with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 5417 and its SIC code is 8731.